Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AIM ImmunoTech Inc.AIM · Entity 8131 | Chief Financial Officer | April 04, 2022 | April 04, 2022 |
| AngioGenex, Inc.AGGX · Entity 130294 | Director · INDEPENDENT DIRECTOR | December 31, 2021 | February 16, 2022 |
| EMMAUS LIFE SCIENCES, INC.NONE · Entity 156030 | Director | September 27, 2018 | September 28, 2018 |
| Emmaus Life Sciences, Inc.EMMA · Entity 205 | Director | July 17, 2019 | July 30, 2019 |
| Enveric Biosciences, Inc.ENVB · Entity 8193 | Chief Financial Officer | September 09, 2022 | September 23, 2022 |
| Invitae CorpNVTA · Entity 95935 | See Remarks | August 14, 2023 | August 17, 2023 |
| Vyome Holdings, IncHIND · Entity 1824 | Chief Financial Officer | August 15, 2025 | September 11, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AIM ImmunoTech Inc.
Report date April 04, 2022 · Filed April 04, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.70 · Expires 2032-03-03 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2022-04-04 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed |
AngioGenex, Inc.
Report date December 31, 2021 · Filed February 16, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $0.13 · Expires 2026-09-02 | Direct | 850,000 |
Reported balance
After 2021-09-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-09-02 · Grant · Acquired 250,000 · Balance 850,000 |
EMMAUS LIFE SCIENCES, INC.
Report date September 27, 2018 · Filed September 28, 2018
This filing explicitly reported no securities owned.
Emmaus Life Sciences, Inc.
Report date July 17, 2019 · Filed July 30, 2019
This filing explicitly reported no securities owned.
Enveric Biosciences, Inc.
Report date September 09, 2022 · Filed September 23, 2022
This filing explicitly reported no securities owned.
Invitae Corp
Report date August 14, 2023 · Filed August 17, 2023
This filing explicitly reported no securities owned.
Vyome Holdings, Inc
Report date August 15, 2025 · Filed September 11, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 762 |
Reported balance
After 2025-08-15 transaction · row 1
1 source rowRow 1 · 2025-08-15 · Grant · Acquired 762 · Balance 762 F1: Under the terms of the Agreement and Plan of Merger, dated as of July 8, 2024, as amended (the "Merger Agreement"), by and among the Issuer, Raider Lifesciences Inc., a wholly owned subsidiary of the Issuer ("Merger Sub"), and Vyome Therapeutics, Inc. ("Vyome Therapeutics"), on August 15, 2025, Merger Sub merged with and into Vyome Therapeutics, with Vyome Therapeutics surviving the merger as a subsidiary of the Issuer (the "Merger"). Upon the closing of the Merger, each share of common and preferred stock of Vyome Therapeutics, was converted into the right to receive 1 share of the Issuer's common stock for every 5,000 shares of Vyome Therapeutics. As a result of the Merger, the Issuer was renamed "Vyome Holdings, Inc." and Vyome Therapeutics continued under its name as Vyome Therapeutics, Inc. The reporting person received 762 shares of the Issuer's common stock in exchange for 3,810,000 shares of common stock of Vyome Therapeutics pursuant to the Merger Agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: Under the terms of the Agreement and Plan of Merger, dated as of July 8, 2024, as amended (the "Merger Agreement"), by and among the Issuer, Raider Lifesciences Inc., a wholly owned subsidiary of the Issuer ("Merger Sub"), and Vyome Therapeutics, Inc. ("Vyome Therapeutics"), on August 15, 2025, Merger Sub merged with and into Vyome Therapeutics, with Vyome Therapeutics surviving the merger as a subsidiary of the Issuer (the "Merger"). Upon the closing of the Merger, each share of common and preferred stock of Vyome Therapeutics, was converted into the right to receive 1 share of the Issuer's common stock for every 5,000 shares of Vyome Therapeutics. As a result of the Merger, the Issuer was renamed "Vyome Holdings, Inc." and Vyome Therapeutics continued under its name as Vyome Therapeutics, Inc. The reporting person received 762 shares of the Issuer's common stock in exchange for 3,810,000 shares of common stock of Vyome Therapeutics pursuant to the Merger Agreement.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 15, 2025 Filed Sep 11, 2025 21:21 UTC | Vyome Holdings, Inc HIND · Entity 1824 | GrantCommon Stock | 762 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-25-086999 · ownership.xml · nonDerivative · entry 1 Dickey Robert IV · CIK 0001466862 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 762 F1 · kind: Under the terms of the Agreement and Plan of Merger, dated as of July 8, 2024, as amended (the "Merger Agreement"), by and among the Issuer, Raider Lifesciences Inc., a wholly owned subsidiary of the Issuer ("Merger Sub"), and Vyome Therapeutics, Inc. ("Vyome Therapeutics"), on August 15, 2025, Merger Sub merged with and into Vyome Therapeutics, with Vyome Therapeutics surviving the merger as a subsidiary of the Issuer (the "Merger"). Upon the closing of the Merger, each share of common and preferred stock of Vyome Therapeutics, was converted into the right to receive 1 share of the Issuer's common stock for every 5,000 shares of Vyome Therapeutics. As a result of the Merger, the Issuer was renamed "Vyome Holdings, Inc." and Vyome Therapeutics continued under its name as Vyome Therapeutics, Inc. The reporting person received 762 shares of the Issuer's common stock in exchange for 3,810,000 shares of common stock of Vyome Therapeutics pursuant to the Merger Agreement. F1 · price: Under the terms of the Agreement and Plan of Merger, dated as of July 8, 2024, as amended (the "Merger Agreement"), by and among the Issuer, Raider Lifesciences Inc., a wholly owned subsidiary of the Issuer ("Merger Sub"), and Vyome Therapeutics, Inc. ("Vyome Therapeutics"), on August 15, 2025, Merger Sub merged with and into Vyome Therapeutics, with Vyome Therapeutics surviving the merger as a subsidiary of the Issuer (the "Merger"). Upon the closing of the Merger, each share of common and preferred stock of Vyome Therapeutics, was converted into the right to receive 1 share of the Issuer's common stock for every 5,000 shares of Vyome Therapeutics. As a result of the Merger, the Issuer was renamed "Vyome Holdings, Inc." and Vyome Therapeutics continued under its name as Vyome Therapeutics, Inc. The reporting person received 762 shares of the Issuer's common stock in exchange for 3,810,000 shares of common stock of Vyome Therapeutics pursuant to the Merger Agreement. Read SEC document |
| September 02, 2021 Filed Feb 16, 2022 13:49 UTC | AngioGenex, Inc. AGGX · Entity 130294 | GrantStock Option · Derivative | 250,000 | $0.13 Strike: $0.13 | $32,500.00 |
DisclosureSEC source: 0001469709-22-000011 · ownership.xml · derivative · entry 1 Dickey Robert IV · CIK 0001466862 · Director · INDEPENDENT DIRECTOR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 850,000 Underlying: Common Stock · 250,000 shares Expires 2026-09-02 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.